Doxycycline Hyclate Delayed-Release 200 mg
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gonorrhea
Conditions
Gonorrhea, Chlamydia, Syphilis
Trial Timeline
Nov 26, 2019 → Jun 12, 2023
NCT ID
NCT03980223About Doxycycline Hyclate Delayed-Release 200 mg
Doxycycline Hyclate Delayed-Release 200 mg is a approved stage product being developed by Mayne Pharma Group for Gonorrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT03980223. Target conditions include Gonorrhea, Chlamydia, Syphilis.
What happened to similar drugs?
0 of 1 similar drugs in Gonorrhea were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03980223 | Approved | Completed |
Competing Products
2 competing products in Gonorrhea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trumenba Vaccine + MenACWY Vaccine | Pfizer | Pre-clinical | 26 |
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 34 |